

Supplementary Table1. Comparison of characteristics according to SHMT2 expression in patients with PTC

	SHMT2 negative (n=34)	SHMT2 positive (n=95)	<i>P</i> value
Sex			0.203
Male	9 (26.5%)	14 (14.7%)	
Female	25 (73.5%)	81 (85.3%)	
Age, (years)	44.7 (29.6–51.5)	50.6 (42.1–57.3)	0.004
Age ≥ 55	5 (14.7%)	30 (31.6%)	0.094
Thyroid surgery			0.384
Lobectomy	4 (11.8%)	5 (5.3%)	
TT ± CND	17 (50.0%)	56 (58.9%)	
TT + MRND	13 (38.2%)	34 (35.8%)	
Tumor size, (cm)	2.3 (1.6–3.0)	2.2 (1.6–3.1)	0.851
Tumor size <2cm	16 (47.1%)	45 (47.4%)	0.791
2cm<tumor size <4cm	13 (38.2%)	40 (42.1%)	
Tumor size > 4cm	5 (14.7%)	10 (10.5%)	
Extrathyroid extension			0.727
Microscopic	11 (32.4%)	29 (30.5%)	
Gross	14 (41.2%)	46 (48.4%)	
T stage (8th edition)			0.693
T1	11 (32.4%)	27 (28.4%)	
T2	7 (20.6%)	19 (20.0%)	
T3	9 (26.5%)	35 (36.8%)	
T4	7 (20.6%)	14 (14.7%)	
N stage (8th edition)			0.157
No/Nx	6 (17.6%)	15 (15.8%)	
N1a	5 (14.7%)	5 (5.3%)	
N1b	13 (38.2%)	33 (34.7%)	
M stage (8th edition)			0.108
M0	28 (82.4%)	89 (93.7%)	
M1	6 (17.6%)	6 (6.3%)	
TNM stage (8th edition)			0.694
Stage I	27 (79.4%)	70 (73.7%)	

Stage II	4 (11.8%)	18 (18.9%)
Stage III	1 (2.9%)	4 (4.2%)
Stage IV	2 (5.9%)	3 (3.2%)

Continuous variables were presented as median and interquartile range (IQR) and categorical variables were presented as number (percentage). *SHMT2* serine hydroxymethyltransferase2
PTC papillary thyroid carcinoma; *TNM* tumor-node-metastasis